

# CITATION REPORT

List of articles citing

**In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect**

**DOI: 10.1016/j.micpath.2020.104228**  
**Microbial Pathogenesis, 2020, 145, 104228.**

**Source:** <https://exaly.com/paper-pdf/77587556/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
218	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. <b>2020</b> , 20, 1-112		2
217	Methylene blue inhibits replication of SARS-CoV-2 in vitro. <b>2020</b> , 56, 106202		29
216	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <b>2020</b> , 37, 101873		38
215	Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. <b>2020</b> , 28, 2040206620961712		12
214	Druggable targets from coronaviruses for designing new antiviral drugs. <b>2020</b> , 28, 115745		10
213	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <b>2020</b> , 262, 118541		4
212	Critical reappraisal of remdesivir investigational trials in COVID-19. <b>2020</b> , 38, 100745		1
211	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. <b>2020</b> , 13, 463-484		5
210	The immuno-oncological challenge of COVID-19.. <b>2020</b> , 1, 946-964		52
209	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. <b>2020</b> , 9,		23
208	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <b>2020</b> , 4, 121-131		
207	Emerging Therapeutic Modalities against COVID-19. <b>2020</b> , 13,		11
206	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <b>2020</b> , 21,		27
205	Drug Discovery Strategies for SARS-CoV-2. <b>2020</b> , 375, 127-138		51
204	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. <b>2021</b> , 39, 6828-6841		24
203	Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. <b>2020</b> , 99, 437-440		46
202	No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19. <b>2020</b> , 51, 1765-1769		4

201	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. <b>2020</b> , 56, 106214	53
200	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. <b>2020</b> , 161, 105250	21
199	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <b>2020</b> , 11, 562264	5
198	QT interval measurement with portable device during COVID-19 outbreak. <b>2020</b> , 30, 100644	2
197	The Strengths of Scanning Electron Microscopy in Deciphering SARS-CoV-2 Infectious Cycle. <b>2020</b> , 11, 2014	24
196	Drug repurposing for COVID-19: a potential threat of self-medication and controlling measures. <b>2021</b> , 97, 742-743	18
195	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. <b>2020</b> , 25, 1108-1122	20
194	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <b>2020</b> , 21, 718	15
193	Can We Test Our Way Out of the COVID-19 Pandemic?. <b>2020</b> , 58,	22
192	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. <b>2020</b> , 11, 1969	5
191	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. <b>2020</b> , 18, 17	13
190	Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e22031	1
189	A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. <b>2020</b> , 59, 102936	10
188	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. <b>2020</b> , 25,	4
187	COVID-19 Therapeutic Options Under Investigation. <b>2020</b> , 11, 1196	49
186	New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. <b>2020</b> , 21,	15
185	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. <b>2020</b> , 8,	61
184	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. <b>2020</b> , 11, 595888	23

183	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. <b>2020</b> , 11, 586572	30
182	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. <b>2020</b> , 25,	42
181	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <b>2020</b> , 80, 1961-1972	13
180	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. <b>2020</b> , 35, 101738	300
179	Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?. <b>2020</b> , 60, 808-814	13
178	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). <b>2020</b> , 40, 591-601	55
177	Potential Antiviral Options against SARS-CoV-2 Infection. <b>2020</b> , 12,	62
176	Remdesivir investigational trials in COVID-19: a critical reappraisal. <b>2020</b> , 100707	3
175	Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. <b>2020</b> , 38, 100709	48
174	Azithromycin for COVID-19: More Than Just an Antimicrobial?. <b>2020</b> , 40, 683-686	54
173	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <b>2020</b> , 97, 396-403	330
172	Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. <b>2020</b> , 73, 109706	13
171	Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. <b>2020</b> , 9,	34
170	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <b>2020</b> , 36, 101791	162
169	Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. <b>2020</b> , 108, 201-211	100
168	Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. <b>2021</b> , 1228, 129459	5
167	Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. <b>2021</b> , 147, 111887	6
166	Interferon-inducer antivirals: Potential candidates to combat COVID-19. <b>2021</b> , 91, 107245	17

165	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <b>2021</b> , 133, 111008	14
164	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. <b>2021</b> , 54, e12953	8
163	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. <b>2021</b> , 90, 107228	12
162	[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine]. <b>2021</b> , 156, 166-171	0
161	Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. <b>2021</b> , 29, 1-11	69
160	Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). <b>2021</b> , 4, 1-13	10
159	Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. <b>2021</b> , 538, 132-136	21
158	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134	26
157	Community use of antibiotics during the COVID-19 lockdown. <b>2021</b> , 53, 142-144	8
156	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. <b>2021</b> , 72, e558-e565	61
155	Azithromycin in viral infections. <b>2021</b> , 31, e2163	36
154	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <b>2021</b> , 27, 19-27	144
153	Azithromycin in the treatment of COVID-19: a review. <b>2021</b> , 19, 147-163	71
152	COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review.	1
151	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. <b>2021</b> , 12, 6	7
150	Drug Combinations. <b>2021</b> ,	
149	The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort. <b>2021</b> , 10, 439-455	8
148	Therapeutic and Vaccine Strategies for Stopping the COVID-19 Pandemic Based on Structural and Molecular Modeling Studies of Virus-Ganglioside Interactions. <b>2021</b> , 273	

147	In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea.	2
146	Multi-Compartment Lymph-Node-on-a-Chip Enables Measurement of Immune Cell Motility in Response to Drugs. <b>2021</b> , 8,	4
145	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. <b>2020</b> , 11, 571416	126
144	Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. <b>2021</b> , 11, e042965	2
143	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <b>2021</b> ,	5
142	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <b>2021</b> , 22, 1127-1141	3
141	Focus on azithromycin. <b>2021</b> , 2, 6-8	1
140	Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. <b>2021</b> , 156, 166-171	1
139	Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?. <b>2021</b> , 54, 997-1000	6
138	Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. <b>2021</b> , 104, 250-254	51
137	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. <b>2021</b> , 27, 281-290	8
136	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <b>2021</b> , 895, 173890	41
135	Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon. <b>2021</b> ,	2
134	Computational guided approach for drug repurposing against SARS-CoV-2. <b>2021</b> , 16, 211-243	3
133	Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model. <b>2021</b> , 269, 119099	1
132	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <b>2021</b> , 17, 24	7
131	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. <b>2021</b> , 12, 589095	32
130	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. <b>2021</b> , 22,	10

129	Utilizaçã De Azitromicina Para O Tratamento Da Covid-19: Uma Visã Crítica. 05-21	
128	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. <b>2021</b> , 12, 576093	10
127	A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 [the ATOMIC2 trial.	2
126	Use of Azithromycin to Treat Covid-19: A Critical View. 05-21	
125	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. <b>2021</b> , 39, 159-170	4
124	Repurposing of antibiotics for clinical management of COVID-19: a narrative review. <b>2021</b> , 20, 37	11
123	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <b>2021</b> , 8, 681-691	2
122	Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. <i>Microbial Pathogenesis</i> , <b>2021</b> , 154, 104809	3.8 2
121	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <b>2021</b> , 238, 569-578	0
120	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. <b>2021</b> , 137, 111330	13
119	Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience. <b>2021</b> , 7,	
118	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. <b>2021</b> , 16, e0251731	5
117	Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. <b>2021</b> , 70, 101497	20
116	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. <b>2021</b> , 10,	2
115	Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. <b>2021</b> , 190, 2405-2419	4
114	Therapeutic approaches to tackle COVID-19: An overview. <b>2021</b> , 8, 121-135	
113	In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2. <b>2021</b> , 10,	2
112	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <b>2021</b> , 505, 108326	19

111	Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation. <b>2021</b> , 333, 115934	28
110	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <b>2021</b> , 18, 154	4
109	The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 121, 705-714	3
108	Current knowledge of COVID-19: Advances, challenges and future perspectives. <b>2021</b> , 3, 202-209	0
107	Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis. <b>2021</b> , 63, 475-480	
106	Effects of Hydroxychloroquine and Azithromycin on iPSC-derived Cardiomyocytes: Considerations for the Treatment of COVID-19 Patients.	1
105	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <b>2021</b> , 93, 6737-6749	4
104	Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part III: A green protocol for facile synthesis of complexes with TCNQ, DDQ, and TFQ acceptors. <b>2021</b> , 335, 116250	10
103	Interactions Between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. <b>2021</b> , 11, 721309	1
102	Reducing SARS-CoV-2 pathological protein activity with small molecules. <b>2021</b> , 11, 383-397	5
101	Functions of Sphingolipids in Pathogenesis During Host-Pathogen Interactions. <b>2021</b> , 12, 701041	2
100	Vaccines for COVID-19: A Review of Feasibility and Effectiveness. <b>2021</b> ,	3
99	Potential drug development and therapeutic approaches for clinical intervention in COVID-19. <b>2021</b> , 114, 105016	4
98	Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients. <b>2021</b> , 14, 1668-1670	1
97	Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against covid-19. <b>2021</b> ,	1
96	Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues. <b>2021</b> , 95, e0153721	4
95	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. <b>2021</b> , 9, 1130-1140	25
94	COVID-19 challenges and its therapeutics. <b>2021</b> , 142, 112015	14



93	Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. <b>2021</b> , 44, 102163	2
92	COVID-19, cytokines, inflammation, and spices: How are they related?. <b>2021</b> , 284, 119201	15
91	Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis. <b>2021</b> , 224, 395-406	65
90	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. <b>2021</b> , 33, 1594-1602	
89	Recent progress in the development of potential drugs against SARS-CoV-2. <b>2021</b> , 2, 100057	0
88	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <b>2021</b> , 53, 166-219	11
87	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. <b>2021</b> , 379-416	7
86	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. <b>2020</b> , 38, 100770	10
85	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <b>2021</b> , 19, 1009-1027	17
84	Natural history of COVID-19 and therapeutic options. <b>2020</b> , 16, 1159-1184	41
83	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19.	1
82	Potential antiviral options against SARS-CoV-2 infection.	6
81	Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19.	1
80	Daytime variation in SARS-CoV-2 infection and cytokine production.	2
79	Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis.	14
78	Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion.	11
77	From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature.	2
76	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <b>2020</b> , 11, 597985	13

75	Should azithromycin be used to treat COVID-19? A rapid review. <b>2020</b> , 4,	21
74	An integrative look at SARS-CoV-2 (Review). <b>2021</b> , 47, 415-434	12
73	Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?. <b>2020</b> , 12, 413-422	8
72	Current status of COVID-19 treatment: An opinion review. <b>2020</b> , 9, 27-37	4
71	The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019. <b>2021</b> , 67, 979-984	0
70	Current treatment strategies for COVID-19 (Review). <b>2021</b> , 24,	2
69	Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19.	1
68	Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.	
67	Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies.	
66	Meta-analysis. <b>2020</b> , 8, 73-87	
65	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.	0
64	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. <b>2020</b> , 59, 207-225	0
63	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. <b>2020</b> , 01,	1
62	Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. <b>2020</b> , 61, 321-334	1
61	Coronavirus and Homo Sapiens.	
60	The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort.	
59	Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy.	
58	Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. <b>2021</b> , 197, 105212	0

57	Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial.. <b>2021</b> , 13, e19902	2
56	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <b>2021</b> , 16, 1341-1370	9
55	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <b>2021</b> , 16, 1415-1451	1
54	Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats.. <b>2022</b> , 129, 105114	2
53	Continued use of azithromycin for mild COVID-19 in India: Evidence and implications?. <b>2021</b> , 10, 4341-4344	0
52	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.	0
51	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.. <b>2022</b> , 17, e0263437	4
50	Antiviral effects of azithromycin: A narrative review.. <b>2022</b> , 147, 112682	1
49	Antimicrobial agents and torsades de pointes. <b>2022</b> , 231-266	
48	Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. <b>2022</b> , 15,	1
47	COVID-19: A systematic review and update on prevention, diagnosis, and treatment.. <b>2022</b> , 3, e115	2
46	Graphite based sensor amended with fumed silica for electro-detecting Azithromycin.	0
45	Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.. <b>2022</b> , 14, 97-115	
44	Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants.. <b>2022</b> , 15,	1
43	Charge-transfer chemistry of two corticosteroids used adjunctively to treat COVID-19. Part I: Complexation of hydrocortisone and dexamethasone donors with DDQ acceptor in five organic solvents.. <b>2022</b> , 357, 119092	1
42	A critical analysis about the supposed role of azithromycin in the treatment of covid-19. <b>2021</b> , 11, 11-21	
41	Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. <b>2021</b> , 2,	3
40	Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trial[]	

- 39 Image\_1.TIF. **2020**,
- 38 Image\_2.TIF. **2020**,
- 37 Image\_3.TIF. **2020**,
- 36 The effect of outpatient antibiotic treatment of coronavirus disease 2019 on the outcomes in the emergency department: a propensity score matching study.. **2022**, 63, 53-61
- 35 Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. **2022**, 0
- 34 Global effect of COVID-19 pandemic on cancer patients and its treatment: A systematic review. **2022**, 2, 100041 1
- 33 Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. **2022**, 12, 44-52 0
- 32 Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. **2022**, 23, 6083 2
- 31 Therapeutic options in coronavirus treatment. **2022**, 101-135
- 30 Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617 0
- 29 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. **2022**, 21-63
- 28 Charge-transfer chemistry of two corticosteroids used adjunctively to treat COVID-19. Part II: The CT reaction of hydrocortisone and dexamethasone donors with TCNQ and fluoranil acceptors in five organic solvents. **2022**, 363, 119878 0
- 27 Azithromycin through the Lens of the COVID-19 Treatment. **2022**, 11, 1063 1
- 26 Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. 0
- 25 Bacterial infection in coronavirus disease 2019 patients: co-infection, super-infection and how it impacts on antimicrobial use. Publish Ahead of Print,
- 24 Antifungal activity of vitamin D3 against *Candida albicans* in vitro and in vivo. **2022**, 265, 127200 0
- 23 Pre-hospital Management of COVID-19: Looking for a Future Perspective. **2022**, 395-419 0
- 22 Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in beagle dogs. 1-9 0

- 21 Effect of Graphite Exfoliation Way on the Efficiency of Exfoliated Graphene for the Determination of Hydroxychloroquine in Urine and Waste Water. **2022**, 169, 097505 ○
- 20 Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study. ○
- 19 Analysis of Azithromycin adverse events in COVID-19 Patients reported to Iraqi Pharmacovigilance center in 2020. **2022**, 22, 35-42 ○
- 18 Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells. **2022**, 105463 1
- 17 A Cross-Sectional Analysis of Self-Medication Patterns during the COVID-19 Pandemic in Ecuador. **2022**, 58, 1678 ○
- 16 Recommendations and Guidelines for the Diagnosis and Management of Coronavirus Disease-19 (COVID-19) Associated Bacterial and Fungal Infections in Taiwan. **2022**, ○
- 15 Macrophages and T cells interplay during SARS-CoV-2 variants infection. 13, 1
- 14 COVID-19 and hepatic injury: Diversity and risk assessment. 29, 425-449 ○
- 13 Hydroxychloroquine: Chemistry and Medicinal Applications. **2023**, 106, ○
- 12 Hospital Antibiotic Use during COVID-19 Pandemic in Italy. **2023**, 12, 168 1
- 11 A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. ○
- 10 A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?. ○
- 9 Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era. **2023**, 15, 284 ○
- 8 Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future. **2023**, 24, 1923 ○
- 7 Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in SB Paulo, Brazil: A non-randomized clinical trial preliminary study. **2023**, e15337 ○
- 6 Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic. **2023**, 162, 114681 ○
- 5 Unveiling the Potentiality of Shikonin Derivatives Inhibiting SARS-CoV-2 Main Protease by Molecular Dynamic Simulation Studies. **2023**, 24, 3100 ○
- 4 Prevalence and reasons for self-medication for prevention of COVID -19 among the adult population in Kermanshah-Iran. ○

- 3 The main treatments used for SARS-CoV-2 patients. **2022**, 3, 095-103 ○
- 2 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 1 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○